Kenneth Harrison

Senior Partner at Novo Holdings · Joined 2015

View Live Interactive Profile →

Biography

Kenneth Harrison joined Novo Holdings Venture Investments (US) Inc. in San Francisco in 2015 and is a Senior Partner. Before Novo Holdings he was a Senior Market Planning Manager at Genentech, helping guide strategic decision making for the ophthalmology and HER2 franchises. Earlier he worked as a management consultant at L.E.K. Consulting and as Entrepreneurship Program Manager at QB3/Mission Bay Capital, where he helped create programmes to launch and support life sciences companies in the Bay Area. He holds a PhD in pharmacology from Yale University and a BS in molecular biology from Texas Tech University, and was an A.P. Giannini Foundation Fellow at the J. David Gladstone Institutes.

Education

Previous Experience

Notable Investments

SiteOne TherapeuticsHillstar BioExpedition TherapeuticsCrystalys Therapeutics

Board Seats

Career Timeline

2015
Joins Novo Holdings Venture Investments (US) Inc. in San Francisco.
2024
Named in Novo Holdings' announcement of SiteOne Therapeutics' $100m Series C as joining the SiteOne board of directors.
2025
Named in Novo Holdings' announcements of Hillstar Bio's Series A and Expedition Therapeutics' Series A as joining both boards of directors.

Sources & References

Novo Holdings - Kenneth Harrison (people page, checked 6 September 2026) ↗Novo Holdings leads $100m Series C financing for SiteOne Therapeutics (18 December 2024) ↗Novo Holdings co-leads $67 million Series A funding in Hillstar Bio (26 March 2025) ↗Novo Holdings co-leads $165 million Series A financing of Expedition Therapeutics (9 October 2025) ↗Novo Holdings co-leads $205 million Series A financing of Crystalys Therapeutics (30 September 2025) ↗